JP7705884B2 - ガレクチン－３の低分子阻害剤 - Google Patents

ガレクチン－３の低分子阻害剤 Download PDF

Info

Publication number
JP7705884B2
JP7705884B2 JP2022567342A JP2022567342A JP7705884B2 JP 7705884 B2 JP7705884 B2 JP 7705884B2 JP 2022567342 A JP2022567342 A JP 2022567342A JP 2022567342 A JP2022567342 A JP 2022567342A JP 7705884 B2 JP7705884 B2 JP 7705884B2
Authority
JP
Japan
Prior art keywords
mmol
fluorophenyl
triazol
give
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022567342A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021226002A5 (https=
JP2023524996A (ja
JP2023524996A5 (https=
Inventor
ラオ ジャラガム，プラサダ
ケサバン ナイル，サティーシュ
ジェタナンド ナラ，スシール
パンダ，マノランジャン
デバステール，プラティク
レゲイロ－レン，アリシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2023524996A publication Critical patent/JP2023524996A/ja
Publication of JPWO2021226002A5 publication Critical patent/JPWO2021226002A5/ja
Publication of JP2023524996A5 publication Critical patent/JP2023524996A5/ja
Application granted granted Critical
Publication of JP7705884B2 publication Critical patent/JP7705884B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022567342A 2020-05-05 2021-05-04 ガレクチン－３の低分子阻害剤 Active JP7705884B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063020041P 2020-05-05 2020-05-05
US63/020,041 2020-05-05
PCT/US2021/030540 WO2021226002A1 (en) 2020-05-05 2021-05-04 Small molecule inhibitors of galectin-3

Publications (4)

Publication Number Publication Date
JP2023524996A JP2023524996A (ja) 2023-06-14
JPWO2021226002A5 JPWO2021226002A5 (https=) 2024-05-16
JP2023524996A5 JP2023524996A5 (https=) 2024-05-16
JP7705884B2 true JP7705884B2 (ja) 2025-07-10

Family

ID=76076509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567342A Active JP7705884B2 (ja) 2020-05-05 2021-05-04 ガレクチン－３の低分子阻害剤

Country Status (6)

Country Link
US (1) US12275720B2 (https=)
EP (1) EP4146646A1 (https=)
JP (1) JP7705884B2 (https=)
KR (1) KR20230006547A (https=)
CN (1) CN115551855A (https=)
WO (1) WO2021226002A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2631509A (en) * 2023-07-04 2025-01-08 Univ Liverpool Compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126435A1 (en) 2009-04-28 2010-11-04 Forskarpatent I Syd Ab Novel galactoside inhibitors of galectins
WO2018209255A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
WO2018209276A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
WO2019241461A1 (en) 2018-06-15 2019-12-19 Bristol-Myers Squibb Company Tetrahydropyran-based thiodisaccharide mimics as galectin-3 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401301D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors of galectins
SE0401300D0 (sv) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
US8828971B2 (en) 2012-10-10 2014-09-09 Galectin Therapeutics, Inc. Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders
JP2015535233A (ja) 2012-10-31 2015-12-10 ガレクト・バイオテック・エイビイ ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用
JP6904906B2 (ja) 2015-01-30 2021-07-21 ガレクト・バイオテック・エイビイ ガレクチンの新規なガラクトシド阻害剤
ES2921500T3 (es) 2015-11-09 2022-08-26 Galecto Biotech Ab 1,1'-sulfanodiil-di-beta-d-galactopiranósidos como inhibidores de galectinas

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126435A1 (en) 2009-04-28 2010-11-04 Forskarpatent I Syd Ab Novel galactoside inhibitors of galectins
WO2018209255A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
WO2018209276A1 (en) 2017-05-12 2018-11-15 Galectin Sciences, Llc Compounds for the treatment of systemic insulin resistance disorders and the use thereof
WO2019241461A1 (en) 2018-06-15 2019-12-19 Bristol-Myers Squibb Company Tetrahydropyran-based thiodisaccharide mimics as galectin-3 inhibitors

Also Published As

Publication number Publication date
EP4146646A1 (en) 2023-03-15
WO2021226002A1 (en) 2021-11-11
KR20230006547A (ko) 2023-01-10
JP2023524996A (ja) 2023-06-14
US12275720B2 (en) 2025-04-15
CN115551855A (zh) 2022-12-30
US20230192672A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JP7514025B2 (ja) Ｊａｋ阻害剤化合物及びその使用
CN105916855B (zh) 作为酪蛋白激酶1d/e抑制剂的取代的4，5，6，7-四氢吡唑并[1，5-a]吡嗪衍生物
CN106458912B (zh) 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途
CN104884458B (zh) 作为蛋白质激酶抑制剂的稠合杂环化合物
EP3768260B1 (en) Oxadiazole compounds as transient receptor potential channel inhibitors
CN114072407A (zh) 靶向prmt5的化合物
WO2021139775A1 (zh) 吡啶酮化合物及应用
TW201829411A (zh) 作為Ｒｈｏ－激酶抑制劑之雙環二氫嘧啶－羧醯胺衍生物
CN106687446A (zh) 作为t790m/wt‑egfr的选择性和不可逆的激酶抑制剂的5‑氨基‑4‑氨甲酰基‑吡唑化合物及其用途
KR20220140710A (ko) 트리아졸로피리다진 유도체, 이의 제조 방법, 약물 조성물 및 용도
CN113453680A (zh) 二氢乳清酸脱氢酶抑制剂
CN109689664B (zh) 作为par4抑制剂的三环杂芳基取代的喹啉和氮杂喹啉化合物
JP7478165B2 (ja) ガレクチン－３の低分子阻害剤
JP7190513B2 (ja) ガレクチン－３抑制剤を模したテトラヒドロピラン系チオ二糖類
JP7705884B2 (ja) ガレクチン－３の低分子阻害剤
CN112513041B (zh) 三环化合物
JP7772718B2 (ja) ガレクチン－３阻害剤
JP7677995B2 (ja) ガレクチン－３の低分子阻害剤
CN120303275A (zh) 唾液酸衍生物及其使用方法
WO2025218811A1 (zh) pan-KRAS靶向蛋白降解剂及其制备方法和应用
JP2022511094A (ja) ガレクチン－３の低分子阻害剤
HK40076948B (zh) Kras g12d抑制剂
HK40060484A (en) Dihydroorotate dehydrogenase inhibitors
WO2016204134A1 (ja) ６員ヘテロ環誘導体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250605

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250624

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250630

R150 Certificate of patent or registration of utility model

Ref document number: 7705884

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150